419 related articles for article (PubMed ID: 24476519)
1. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
2. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
3. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
4. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Gold DV; Newsome G; Liu D; Goldenberg DM
Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
[TBL] [Abstract][Full Text] [Related]
5. Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm.
Cao W; Adley BP; Liao J; Lin X; Talamonti M; Bentrem DJ; Rao SM; Yang GY
Hum Pathol; 2010 Apr; 41(4):513-21. PubMed ID: 19954814
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of immunohistochemical IMP3 expression in core needle biopsies of pancreatic ductal adenocarcinoma.
Wachter DL; Schlabrakowski A; Hoegel J; Kristiansen G; Hartmann A; Riener MO
Am J Surg Pathol; 2011 Jun; 35(6):873-7. PubMed ID: 21566520
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts.
Yip-Schneider MT; Wu H; Dumas RP; Hancock BA; Agaram N; Radovich M; Schmidt CM
J Am Coll Surg; 2014 Apr; 218(4):608-17. PubMed ID: 24491241
[TBL] [Abstract][Full Text] [Related]
8. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas].
Ji Y; Tan YS; Zhu XZ; Zeng HY; Kuang TT; Jin DY
Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):77-81. PubMed ID: 16630480
[TBL] [Abstract][Full Text] [Related]
11. Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma.
Khan IA; Rashid S; Singh N; Rashid S; Singh V; Gunjan D; Das P; Dash NR; Pandey RM; Chauhan SS; Gupta S; Saraya A
Sci Rep; 2021 Feb; 11(1):2824. PubMed ID: 33531550
[TBL] [Abstract][Full Text] [Related]
12. [Cystic pancreatic tumors: diagnostics and new biomarkers].
Berger AW; Seufferlein T; Kleger A
Chirurg; 2017 Nov; 88(11):905-912. PubMed ID: 28831506
[TBL] [Abstract][Full Text] [Related]
13. Blood small extracellular vesicles derived miRNAs to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Guo S; Qin H; Liu K; Wang H; Bai S; Liu S; Shao Z; Zhang Y; Song B; Xu X; Shen J; Zeng P; Shi X; Chen H; Gao S; Xu J; Pan Y; Xiong L; Li F; Zhang D; Jiao X; Jin G
Clin Transl Med; 2021 Sep; 11(9):e520. PubMed ID: 34586739
[TBL] [Abstract][Full Text] [Related]
14. [Strategy in intraductal papillary mucinous neoplasm of the pancreas].
Navarro Colás S; Vaquero Raya EC
Gastroenterol Hepatol; 2012 Nov; 35(9):652-9. PubMed ID: 22832084
[TBL] [Abstract][Full Text] [Related]
15. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
16. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
[TBL] [Abstract][Full Text] [Related]
17. [Pancreatic incidentalomas. Correct assessment and therapy].
Hopt U; Keck T
Chirurg; 2007 Aug; 78(8):713-20. PubMed ID: 17628760
[TBL] [Abstract][Full Text] [Related]
18. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
19. Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer.
Akashi T; Oimomi H; Nishiyama K; Nakashima M; Arita Y; Sumii T; Kimura T; Ito T; Nawata H; Watanabe T
Pancreas; 2003 Jan; 26(1):49-55. PubMed ID: 12499917
[TBL] [Abstract][Full Text] [Related]
20. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy.
Das KK; Brown JW; Fernandez Del-Castillo C; Huynh T; Mills JC; Matsuda Y; Das KM; Mino-Kenudson M
Hum Pathol; 2021 May; 111():36-44. PubMed ID: 33524436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
